Business Description
Alnylam Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US02043Q1076
Share Class Description:
FRA:DUL: Ordinary SharesTotal Employee Number:
2,500Compare
Compare
Traded in other countries / regions
ALNY.USAA1LN34.Brazil0HD2.UKDUL.GermanyALNY.Mexico1ALNY.Italy IPO Date
2004-05-28Description
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.36 | |||||
Equity-to-Asset | 0.21 | |||||
Debt-to-Equity | 1.18 | |||||
Debt-to-EBITDA | 1.38 | |||||
Interest Coverage | 2.66 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 6.48 | |||||
Beneish M-Score | -1.74 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 47.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 77.06 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 32.68 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 85.69 | |||||
9-Day RSI | 74.37 | |||||
14-Day RSI | 66.17 | |||||
3-1 Month Momentum % | -5.22 | |||||
6-1 Month Momentum % | -24.76 | |||||
12-1 Month Momentum % | -5.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.13 | |||||
Quick Ratio | 3.06 | |||||
Cash Ratio | 2.23 | |||||
Days Inventory | 33.7 | |||||
Days Sales Outstanding | 61.5 | |||||
Days Payable | 49.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.2 | |||||
Shareholder Yield % | 0.03 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 80.83 | |||||
Operating Margin % | 17.55 | |||||
Net Margin % | 13.47 | |||||
EBITDA Margin % | 21.57 | |||||
FCF Margin % | 14.97 | |||||
OCF Margin % | 16.64 | |||||
ROE % | 117.11 | |||||
ROA % | 12.16 | |||||
ROIC % | 59.38 | |||||
3-Year ROIIC % | 380.7 | |||||
ROC (Joel Greenblatt) % | 124.35 | |||||
ROCE % | 25.61 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 85.53 | |||||
Forward PE Ratio | 42.86 | |||||
PE Ratio without NRI | 54.63 | |||||
Price-to-Owner-Earnings | 889.32 | |||||
PS Ratio | 9.93 | |||||
PB Ratio | 38.84 | |||||
Price-to-Tangible-Book | 38.83 | |||||
Price-to-Free-Cash-Flow | 66 | |||||
Price-to-Operating-Cash-Flow | 59.41 | |||||
EV-to-EBIT | 46.06 | |||||
EV-to-Forward-EBIT | 29.11 | |||||
EV-to-EBITDA | 43.33 | |||||
EV-to-Forward-EBITDA | 30.04 | |||||
EV-to-Revenue | 9.34 | |||||
EV-to-Forward-Revenue | 7.15 | |||||
EV-to-FCF | 62.27 | |||||
Price-to-GF-Value | 0.6 | |||||
Price-to-Median-PS-Value | 0.29 | |||||
Price-to-Graham-Number | 9.71 | |||||
| Price-to-Net-Current-Asset-Value | 252.78 | |||||
Earnings Yield (Greenblatt) % | 2.17 | |||||
FCF Yield % | 1.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alnylam Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3,681.43 | ||
| EPS (TTM) (€) | 3.132 | ||
| Beta | 0.1355 | ||
| 3-Year Sharpe Ratio | 0.42 | ||
| 3-Year Sortino Ratio | 0.97 | ||
| Volatility % | 36.5 | ||
| 14-Day RSI | 66.17 | ||
| 14-Day ATR (€) | 6.362188 | ||
| 20-Day SMA (€) | 255.04 | ||
| 12-1 Month Momentum % | -5.7 | ||
| 52-Week Range (€) | 238.3 - 423 | ||
| Shares Outstanding (Mil) | 133.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alnylam Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alnylam Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-30 08:30 | In 116 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 115 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-31 08:30 | In 25 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 24 days | ||
| RNAi Roundtable: ALN-6400, Targeting Plasminogen to Address Rare Bleeding Disorders | 2026-06-25 11:00 | 258.80 (+2.94%) | ||
| Goldman Sachs Annual Healthcare Conference | 2026-06-09 11:20 | 253.50 (-3.80%) | ||
| General meeting for 2026 | 2026-05-20 10:30 | 253.40 (+3.98%) | ||
| BofA Securities Healthcare Conference | 2026-05-13 10:40 | 250.50 (+3.90%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 08:30 | 257.20 (+0.27%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 257.20 (+0.27%) |
Show
Entries
Alnylam Pharmaceuticals Inc Frequently Asked Questions
What is Alnylam Pharmaceuticals Inc(FRA:DUL)'s stock price today?
The current price of FRA:DUL is €273.00. The 52 week high of FRA:DUL is €423.00 and 52 week low is €238.30.
When is next earnings date of Alnylam Pharmaceuticals Inc(FRA:DUL)?
The next earnings date of Alnylam Pharmaceuticals Inc(FRA:DUL) is 2026-07-31 Est..
Does Alnylam Pharmaceuticals Inc(FRA:DUL) pay dividends? If so, how much?
Alnylam Pharmaceuticals Inc(FRA:DUL) does not pay dividend.
Press Release
Articles on Alnylam Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers